The leiomyosarcoma drug market size has grown strongly in recent years. It will grow from $1.18 billion in 2025 to $1.28 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to chemotherapy-based sarcoma treatment, limited surgical outcomes, oncology drug pipeline expansion, hospital-based cancer care, orphan drug incentives.
The leiomyosarcoma drug market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to precision oncology adoption, molecular profiling of tumors, clinical trial expansion for rare cancers, combination immunotherapy development, regulatory support for orphan drugs. Major trends in the forecast period include rising adoption of targeted cancer therapies, expansion of combination treatment regimens, increased focus on rare cancer drug development, growing role of immunotherapy, advancements in precision oncology.
The growing investment in oncology research is expected to drive growth in the leiomyosarcoma drug market in the coming years. Oncology research involves the scientific study of the causes, development, diagnosis, treatment, and prevention of cancer. Investment in this field is increasing due to the rising burden of cancer, which necessitates advanced therapies and improved patient outcomes. Leiomyosarcoma drug development supports oncology research by promoting innovation in targeted treatments and encouraging funding for rare cancer therapies. For example, in 2023, according to the American Society for Radiation Oncology (ASTRO), the National Institutes of Health (NIH) received $51 billion in funding, including $9.988 billion allocated to the National Cancer Institute (NCI), representing a $2.7 billion increase from 2022. Consequently, the growing investment in oncology research is fueling the leiomyosarcoma drug market.
Key companies in the leiomyosarcoma drug market are focusing on developing innovative targeted therapies, such as lurbinectedin-based regimens, to improve outcomes for patients with advanced or treatment-resistant tumors. Lurbinectedin-based regimens are designed to specifically target leiomyosarcoma cells, enhancing therapeutic effectiveness. For instance, in October 2023, Pharma Mar S.A., a Spain-based pharmaceutical company, initiated the Phase IIb/III clinical trial SaLuDo to evaluate the effectiveness of Zepzelca (lurbinectedin) combined with doxorubicin in patients with metastatic leiomyosarcoma. The trial aims to assess whether this combination offers better progression-free and overall survival compared to current treatments. If successful, SaLuDo could establish a new standard of care and provide hope for patients with metastatic leiomyosarcoma.
In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition allows Pfizer to strengthen its oncology portfolio by leveraging Seagen’s antibody-drug conjugate technology, expand its cancer treatment offerings, and drive long-term growth. Seagen Inc. is a US-based biotechnology company specializing in the development and commercialization of cancer therapies.
Major companies operating in the leiomyosarcoma drug market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly And Co, Philogen S.p.A, Eisai Co. Ltd, Incyte Corp, PharmaMar SA, Karyopharm Therapeutics Inc., Taiho Pharmaceutical Co. Ltd., Agenus Inc., Adaptimmune Therapeutics plc, BioInvent International AB, Advenchen Laboratories LLC, Radiopharm Theranostics Limited.
North America was the largest region in the leiomyosarcoma drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leiomyosarcoma drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leiomyosarcoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created cost pressures in the leiomyosarcoma drug market by increasing prices for oncology APIs, biologics, sterile injectables, and advanced drug-delivery systems. Targeted therapies, immunotherapies, and combination treatments are most affected, particularly in North America and Europe due to heavy reliance on imported oncology ingredients. Hospitals, specialized cancer clinics, and research laboratories face higher treatment and procurement costs. On the positive side, tariffs are driving investment in domestic oncology drug manufacturing and clinical research infrastructure, strengthening long-term treatment availability.
The leiomyosarcoma drug market research report is one of a series of new reports that provides leiomyosarcoma drug market statistics, including leiomyosarcoma drug industry global market size, regional shares, competitors with a leiomyosarcoma drug market share, detailed leiomyosarcoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the leiomyosarcoma drug industry. This leiomyosarcoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Leiomyosarcoma drugs are pharmaceutical treatments specifically designed to manage or inhibit the growth of leiomyosarcoma, a rare cancer originating in smooth muscle tissue. These drugs work by targeting the biological pathways that allow tumor cells to grow, divide, and spread throughout the body.
The main types of leiomyosarcoma drugs include chemotherapy agents, targeted therapy, immunotherapy, radiation therapy, and combination therapy. Chemotherapy agents kill or inhibit the growth of cancer cells by disrupting their ability to divide and multiply. They include various classes such as anthracyclines, alkylating agents, antimetabolites, and others, and can be administered orally, intravenously, subcutaneously, topically, or intramuscularly. These drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, serving end users including hospitals, specialized clinics, research laboratories, homecare settings, and pharmaceutical companies.
The leiomyosarcoma drug market consists of sales of trabectedin, pazopanib, doxorubicin, gemcitabine, and eribulin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The leiomyosarcoma drug market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to precision oncology adoption, molecular profiling of tumors, clinical trial expansion for rare cancers, combination immunotherapy development, regulatory support for orphan drugs. Major trends in the forecast period include rising adoption of targeted cancer therapies, expansion of combination treatment regimens, increased focus on rare cancer drug development, growing role of immunotherapy, advancements in precision oncology.
The growing investment in oncology research is expected to drive growth in the leiomyosarcoma drug market in the coming years. Oncology research involves the scientific study of the causes, development, diagnosis, treatment, and prevention of cancer. Investment in this field is increasing due to the rising burden of cancer, which necessitates advanced therapies and improved patient outcomes. Leiomyosarcoma drug development supports oncology research by promoting innovation in targeted treatments and encouraging funding for rare cancer therapies. For example, in 2023, according to the American Society for Radiation Oncology (ASTRO), the National Institutes of Health (NIH) received $51 billion in funding, including $9.988 billion allocated to the National Cancer Institute (NCI), representing a $2.7 billion increase from 2022. Consequently, the growing investment in oncology research is fueling the leiomyosarcoma drug market.
Key companies in the leiomyosarcoma drug market are focusing on developing innovative targeted therapies, such as lurbinectedin-based regimens, to improve outcomes for patients with advanced or treatment-resistant tumors. Lurbinectedin-based regimens are designed to specifically target leiomyosarcoma cells, enhancing therapeutic effectiveness. For instance, in October 2023, Pharma Mar S.A., a Spain-based pharmaceutical company, initiated the Phase IIb/III clinical trial SaLuDo to evaluate the effectiveness of Zepzelca (lurbinectedin) combined with doxorubicin in patients with metastatic leiomyosarcoma. The trial aims to assess whether this combination offers better progression-free and overall survival compared to current treatments. If successful, SaLuDo could establish a new standard of care and provide hope for patients with metastatic leiomyosarcoma.
In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition allows Pfizer to strengthen its oncology portfolio by leveraging Seagen’s antibody-drug conjugate technology, expand its cancer treatment offerings, and drive long-term growth. Seagen Inc. is a US-based biotechnology company specializing in the development and commercialization of cancer therapies.
Major companies operating in the leiomyosarcoma drug market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly And Co, Philogen S.p.A, Eisai Co. Ltd, Incyte Corp, PharmaMar SA, Karyopharm Therapeutics Inc., Taiho Pharmaceutical Co. Ltd., Agenus Inc., Adaptimmune Therapeutics plc, BioInvent International AB, Advenchen Laboratories LLC, Radiopharm Theranostics Limited.
North America was the largest region in the leiomyosarcoma drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leiomyosarcoma drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leiomyosarcoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created cost pressures in the leiomyosarcoma drug market by increasing prices for oncology APIs, biologics, sterile injectables, and advanced drug-delivery systems. Targeted therapies, immunotherapies, and combination treatments are most affected, particularly in North America and Europe due to heavy reliance on imported oncology ingredients. Hospitals, specialized cancer clinics, and research laboratories face higher treatment and procurement costs. On the positive side, tariffs are driving investment in domestic oncology drug manufacturing and clinical research infrastructure, strengthening long-term treatment availability.
The leiomyosarcoma drug market research report is one of a series of new reports that provides leiomyosarcoma drug market statistics, including leiomyosarcoma drug industry global market size, regional shares, competitors with a leiomyosarcoma drug market share, detailed leiomyosarcoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the leiomyosarcoma drug industry. This leiomyosarcoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Leiomyosarcoma drugs are pharmaceutical treatments specifically designed to manage or inhibit the growth of leiomyosarcoma, a rare cancer originating in smooth muscle tissue. These drugs work by targeting the biological pathways that allow tumor cells to grow, divide, and spread throughout the body.
The main types of leiomyosarcoma drugs include chemotherapy agents, targeted therapy, immunotherapy, radiation therapy, and combination therapy. Chemotherapy agents kill or inhibit the growth of cancer cells by disrupting their ability to divide and multiply. They include various classes such as anthracyclines, alkylating agents, antimetabolites, and others, and can be administered orally, intravenously, subcutaneously, topically, or intramuscularly. These drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, serving end users including hospitals, specialized clinics, research laboratories, homecare settings, and pharmaceutical companies.
The leiomyosarcoma drug market consists of sales of trabectedin, pazopanib, doxorubicin, gemcitabine, and eribulin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Leiomyosarcoma Drug Market Characteristics
3. Leiomyosarcoma Drug Market Supply Chain Analysis
4. Global Leiomyosarcoma Drug Market Trends and Strategies
5. Leiomyosarcoma Drug Market Analysis of End Use Industries
7. Global Leiomyosarcoma Drug Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Leiomyosarcoma Drug Total Addressable Market (TAM) Analysis for the Market
9. Leiomyosarcoma Drug Market Segmentation
10. Leiomyosarcoma Drug Market Regional and Country Analysis
11. Asia-Pacific Leiomyosarcoma Drug Market
12. China Leiomyosarcoma Drug Market
13. India Leiomyosarcoma Drug Market
14. Japan Leiomyosarcoma Drug Market
15. Australia Leiomyosarcoma Drug Market
16. Indonesia Leiomyosarcoma Drug Market
17. South Korea Leiomyosarcoma Drug Market
18. Taiwan Leiomyosarcoma Drug Market
19. South East Asia Leiomyosarcoma Drug Market
20. Western Europe Leiomyosarcoma Drug Market
21. UK Leiomyosarcoma Drug Market
22. Germany Leiomyosarcoma Drug Market
23. France Leiomyosarcoma Drug Market
24. Italy Leiomyosarcoma Drug Market
25. Spain Leiomyosarcoma Drug Market
26. Eastern Europe Leiomyosarcoma Drug Market
27. Russia Leiomyosarcoma Drug Market
28. North America Leiomyosarcoma Drug Market
29. USA Leiomyosarcoma Drug Market
30. Canada Leiomyosarcoma Drug Market
31. South America Leiomyosarcoma Drug Market
32. Brazil Leiomyosarcoma Drug Market
33. Middle East Leiomyosarcoma Drug Market
34. Africa Leiomyosarcoma Drug Market
36. Leiomyosarcoma Drug Market Competitive Landscape and Company Profiles
37. Leiomyosarcoma Drug Market Other Major and Innovative Companies
40. Leiomyosarcoma Drug Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Leiomyosarcoma Drug Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses leiomyosarcoma drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for leiomyosarcoma drug? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The leiomyosarcoma drug market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Type: Chemotherapy Agents; Targeted Therapy; Immunotherapy; Radiation Therapy; Combination Therapy2) By Drug Class: Anthracyclines; Alkylating Agents; Antimetabolites; Other Drug Class
3) By Route of Administration: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
5) By End User: Hospitals; Specialized Clinics; Research Laboratories; Homecare Settings; Pharmaceutical Companies
Subsegments:
1) By Chemotherapy Agents: Anthracyclines; Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors; Taxanes2) By Targeted Therapy: Deoxyribonucleic Acid Minor Groove Binders; Tyrosine Kinase Inhibitors; Mechanistic Target Of Rapamycin Inhibitors; Vascular Endothelial Growth Factor Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Adoptive Cell Transfer
4) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy; Intensity-Modulated Radiation Therapy
5) By Combination Therapy: Chemotherapy + Targeted Therapy; Chemotherapy + Radiation Therapy; Immunotherapy + Targeted Therapy
Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Merck And Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca Plc; Novartis AG; GlaxoSmithKline plc; Eli Lilly And Co; Philogen S.p.A; Eisai Co. Ltd; Incyte Corp; PharmaMar SA; Karyopharm Therapeutics Inc.; Taiho Pharmaceutical Co. Ltd.; Agenus Inc.; Adaptimmune Therapeutics plc; BioInvent International AB; Advenchen Laboratories LLC; Radiopharm Theranostics Limited.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Leiomyosarcoma Drug market report include:- Pfizer Inc.
- Johnson And Johnson
- Merck And Co. Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- AstraZeneca Plc
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly And Co
- Philogen S.p.A
- Eisai Co. Ltd
- Incyte Corp
- PharmaMar SA
- Karyopharm Therapeutics Inc.
- Taiho Pharmaceutical Co. Ltd.
- Agenus Inc.
- Adaptimmune Therapeutics plc
- BioInvent International AB
- Advenchen Laboratories LLC
- Radiopharm Theranostics Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.28 Billion |
| Forecasted Market Value ( USD | $ 1.76 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
